Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds
- Resource Type
- Abstract
- Source
- In
Blood 23 November 2021 138 Supplement 1:3356-3356 - Subject
- Language
- ISSN
- 0006-4971